1. Home
  2. RLMD vs PEO Comparison

RLMD vs PEO Comparison

Compare RLMD & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$5.93

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Logo Adams Natural Resources Fund Inc.

PEO

Adams Natural Resources Fund Inc.

HOLD

Current Price

$26.13

Market Cap

737.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLMD
PEO
Founded
2004
1929
Country
United States
United States
Employees
17
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
661.9M
737.4M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
RLMD
PEO
Price
$5.93
$26.13
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$12.40
N/A
AVG Volume (30 Days)
925.0K
74.8K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
5.93%
EPS Growth
45.28
N/A
EPS
N/A
N/A
Revenue
$13,070.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
154.83
N/A
52 Week Low
$0.52
$20.57
52 Week High
$8.00
$28.88

Technical Indicators

Market Signals
Indicator
RLMD
PEO
Relative Strength Index (RSI) 32.00 47.81
Support Level $5.68 $25.37
Resistance Level $7.46 $26.28
Average True Range (ATR) 0.41 0.51
MACD -0.14 0.02
Stochastic Oscillator 5.11 34.48

Price Performance

Historical Comparison
RLMD
PEO

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About PEO Adams Natural Resources Fund Inc.

Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in the petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.

Share on Social Networks: